C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|13|16|1619-1629

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.13, Iss.16, 2007-06, pp. : 1619-1629

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction

By  

Current Pharmaceutical Analysis, Vol. 11, Iss. 1, 2015-02 ,pp. : 60-65

Bentham Science Publishers

Access to resources Recommend Favorite

The biological functions of C-reactive protein

By Szalai A.J.  

General Pharmacology, Vol. 39, Iss. 3, 2002-08 ,pp. : 105-107

Elsevier

Access to resources Recommend Favorite

Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein

By Kluft C.   de Maat M.P.M.  

General Pharmacology, Vol. 39, Iss. 3, 2002-08 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 2, 2013-01 ,pp. : 180-200

Bentham Science Publishers

Access to resources Recommend Favorite

QOL effects of C-reactive protein levels in diabetes

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 442, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite